Jiangsu Hengrui Pharmaceuticals Secures Clinical Trial Approvals for Ten Drug Candidates

Stock News

Sep 23

Jiangsu Hengrui Pharmaceuticals Co.,Ltd. (600276.SH) has announced that it and its subsidiaries recently received Drug Clinical Trial Approval Notices from the National Medical Products Administration for ten drug candidates, paving the way for upcoming clinical studies.

The approved candidates include HRS-7172 tablets, adebrelimab injection, SHR-4610 injection, SHR-8068 injection, SHR-9839 for injection (sc), SHR-1826 for injection, bevacizumab injection, HRS-4642 injection, HRS-6093 tablets, and HRS-7058 capsules.

Per the Drug Administration Law of the People's Republic of China and relevant regulations, after review, the clinical trial applications for the aforementioned drug candidates, which were accepted on May 18, 2026, meet the requirements for drug registration and have been approved for clinical trials.

The specific study outlined is an open-label, multicenter Phase Ib/II clinical study evaluating the safety, tolerability, and efficacy of HRS-7172 in combination with antitumor therapy in participants with solid tumors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1112810908"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1112810908\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1112810908?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-23 16:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112810908","market":"other","top_or_hot":-1,"title":"Jiangsu Hengrui Pharmaceuticals Secures Clinical Trial Approvals for Ten Drug Candidates","media":"Stock News","content":"<p><b>Jiangsu Hengrui Pharmaceuticals Co.,Ltd.</b> (<b>600276.SH</b>) has announced that it and its subsidiaries recently received Drug Clinical Trial Approval Notices from the National Medical Products Administration for ten drug candidates, paving the way for upcoming clinical studies.<br><br>The approved candidates include HRS-7172 tablets, adebrelimab injection, SHR-4610 injection, SHR-8068 injection, SHR-9839 for injection (sc), SHR-1826 for injection, bevacizumab injection, HRS-4642 injection, HRS-6093 tablets, and HRS-7058 capsules.<br><br>Per the Drug Administration Law of the People's Republic of China and relevant regulations, after review, the clinical trial applications for the aforementioned drug candidates, which were accepted on May 18, 2026, meet the requirements for drug registration and have been approved for clinical trials.<br><br>The specific study outlined is an open-label, multicenter Phase Ib/II clinical study evaluating the safety, tolerability, and efficacy of HRS-7172 in combination with antitumor therapy in participants with solid tumors.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jiangsu Hengrui Pharmaceuticals Secures Clinical Trial Approvals for Ten Drug Candidates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJiangsu Hengrui Pharmaceuticals Secures Clinical Trial Approvals for Ten Drug Candidates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-23 16:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Jiangsu Hengrui Pharmaceuticals Co.,Ltd.</b> (<b>600276.SH</b>) has announced that it and its subsidiaries recently received Drug Clinical Trial Approval Notices from the National Medical Products Administration for ten drug candidates, paving the way for upcoming clinical studies.<br><br>The approved candidates include HRS-7172 tablets, adebrelimab injection, SHR-4610 injection, SHR-8068 injection, SHR-9839 for injection (sc), SHR-1826 for injection, bevacizumab injection, HRS-4642 injection, HRS-6093 tablets, and HRS-7058 capsules.<br><br>Per the Drug Administration Law of the People's Republic of China and relevant regulations, after review, the clinical trial applications for the aforementioned drug candidates, which were accepted on May 18, 2026, meet the requirements for drug registration and have been approved for clinical trials.<br><br>The specific study outlined is an open-label, multicenter Phase Ib/II clinical study evaluating the safety, tolerability, and efficacy of HRS-7172 in combination with antitumor therapy in participants with solid tumors.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2148510915.USD","symbol_name":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","start_time":0,"source_url":"","article_id":"1112810908","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112810908","pubTimestamp":1790152956,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd. (600276.SH) has announced that it and its subsidiaries recently received Drug Clinical Trial Approval Notices from the National Medical Products...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","BK0028":"国家队","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","BK1191":"制药","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU0359201612.USD":"贝莱德中国基金A2","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","IBBQ":"Invesco Nasdaq Biotechnology ETF","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","PSYK":"PSYK ETF","BK0060":"抗癌","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","BMED":"iShares Health Innovation Active ETF","LU1997245177.USD":"安联神洲A股基金","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","BK0188":"融资融券","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","MDTX":"Corgi MediaTek 2x Daily ETF","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","BK0196":"行业龙头","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","01276":"恒瑞医药","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK0239":"医药制造","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","BK0183":"MSCI概念","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","BK0012":"证金概念"},"translate_title":"江苏恒瑞医药十个候选药物获得临床试验批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1,"PSYK":1,"01276":1,"MDTX":1,"BMED":1,"IBBQ":1,"IBBJ":1},"content_text":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd. (600276.SH) has announced that it and its subsidiaries recently received Drug Clinical Trial Approval Notices from the National Medical Products Administration for ten drug candidates, paving the way for upcoming clinical studies.The approved candidates include HRS-7172 tablets, adebrelimab injection, SHR-4610 injection, SHR-8068 injection, SHR-9839 for injection (sc), SHR-1826 for injection, bevacizumab injection, HRS-4642 injection, HRS-6093 tablets, and HRS-7058 capsules.Per the Drug Administration Law of the People's Republic of China and relevant regulations, after review, the clinical trial applications for the aforementioned drug candidates, which were accepted on May 18, 2026, meet the requirements for drug registration and have been approved for clinical trials.The specific study outlined is an open-label, multicenter Phase Ib/II clinical study evaluating the safety, tolerability, and efficacy of HRS-7172 in combination with antitumor therapy in participants with solid tumors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}